Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Emergent BioSolutions Inc.

Emergent BioSolutions Reports Financial Results for Full Year 2008

For the full year 2008, total revenues were $178.6 million, in line with the anticipated $179 million as announced earlier this year, and net income was $20.7 million, or $0.69 per share, which was above the anticipated $18 to $20 million announced earlier this year. The 2008 performance was primarily driven by sales of BioThrax® (Anthrax Vaccine Adsorbed), the company’s FDA licensed vaccine for the prevention of anthrax, offset somewhat by a lower level of contracts and grants revenue. For the full year 2007, total revenues were $182.9...

• View Other Issues of Vaccine Weekly
  
• View Other NewsRx Publications